Lv32
390 积分 2024-11-15 加入
Correction to Lancet Oncol 2025; 26: e423–35
1小时前
求助中
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
7天前
已完结
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
7天前
已完结
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022
11天前
已完结
Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
22天前
已关闭
Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design
1个月前
已完结
Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index – A prospective multicentric study using imaging (ISAAC study)
1个月前
已完结
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
1个月前
已完结
A phase I study of Mirvetuximab Soravtansine and gemcitabine in patients with FRα-positive recurrent ovarian, primary peritoneal, fallopian tube, or endometrial cancer, or triple negative breast cancer
1个月前
已完结
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
1个月前
已完结
皖公网安备34019202002308
